Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humulin ® (human insulin)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Humulin® S, Humulin® I, Humulin® M3 100 Units/ml (insulin human): Interaction with other medicinal products and other forms of interaction
Humulin I (isophane insulin), Humulin S (soluble insulin) and Humulin M3 (30% soluble/70% isophane insulin) requirements may increase or decrease in combination with other medicinal products.
A number of medicinal products are known to interact with glucose metabolism and therefore the physician should be consulted when using other medications in addition to human insulin. The physician must therefore take possible interactions into account and should always ask his patients about any medicinal products they take.
Insulin requirements may be increased by substances with hyperglycaemic activity, such as glucocorticoids, thyroid hormones, growth hormone, danazol, beta2- sympatomimetics (such as ritodrine, salbutamol, terbutaline), thiazides.
Insulin requirements may be reduced in the presence of substances with hypoglycaemic activity, such as oral hypoglycaemics (OHA), salicylates (for example, acetylsalicylic acid), certain antidepressants (monoamine oxidase inhibitors), certain angiotensin converting enzyme (ACE) inhibitors (captopril, enalapril), angiotensin II receptor blockers, non-selective beta-blocking agents and alcohol.
Somatostatin analogues (octreotide, lanreotide) may both decrease or increase insulin dose requirements.
Humulin S 100 cartridge Summary of Product Characteristics
Humulin S 100 vial Summary of Product Characteristics Characteristics
Humulin I 100 cartridge Summary of Product Characteristics
Humulin I 100 SPC KwikPen Summary of Product Characteristics
Humulin I 100 SPC vial Summary of Product Characteristics
Humulin M3 100 cartridge Summary of Product Characteristics
Humulin M3 100 KwikPen Summary of Product Characteristics
Humulin M3 100 vial Summary of Product Characteristics
Date of Last Review: 23 May 2022